Plasminogen Activator Inhibitor Type-1 (Part One): Basic Mechanisms, Regulation, and Role for Thromboembolic Disease Kurt Huber OriginalPaper Pages: 183 - 193
Plasminogen Activator Inhibitor Type-1 (Part Two): Role for Failure of Thrombolytic Therapy. PAI-1 Resistance as a Potential Benefit for New Fibrinolytic Agents Kurt Huber OriginalPaper Pages: 195 - 202
Short-Term Comparative Outcomes Associated with the Use of GP IIb/IIIa Antagonists in Patients Undergoing Coronary Intervention Carey KimmelstielRobert PhangRichard C. Becker OriginalPaper Pages: 203 - 209
Elevation in Serum Troponin I Predicts the Benefit of Tirofiban James L. JanuzziClaudia U. ChaeIk-Kyung Jang OriginalPaper Pages: 211 - 215
Relationship Between the Heparin Management Test and the HemoTec Activated Clotting Time in Patients Undergoing Percutaneous Coronary Intervention Sotirios TsimikasReinaldo BeyerAlborz Hassankhani OriginalPaper Pages: 217 - 221
Augmentation of In-Vitro Clot Dissolution by Low Frequency High-Intensity Ultrasound Combined with Antiplatelet and Antithrombotic Drugs Shaul AtarHuai LuoRobert J. Siegel OriginalPaper Pages: 223 - 228
Noninvasive Transthoracic Low Frequency Ultrasound Augments Thrombolysis in a Canine Model of Acute Myocardial Infarction – Evaluation of the Extent of ST-Segment Resolution Yochai BirnbaumHuai LuoRobert J. Siegel OriginalPaper Pages: 229 - 234
Low Molecular Weight Heparin Therapy for Percutaneous Coronary Intervention: A Practice in Evolution Joseph K. ChooDean J. Kereiakes OriginalPaper Pages: 235 - 246
Applying Scientific Criteria to Therapeutic Interchange: A Balanced Analysis of Low-Molecular-Weight Heparins Geno J. MerliGordon J. VanscoyWilliam McCormick OriginalPaper Pages: 247 - 259
Thrombotic Thrombocytopenic Purpura (TTP) and Hemolytic Uremic Syndrome (HUS): The New Thinking Jingxuan LiuMichael HutzlerLiberto Pechet OriginalPaper Pages: 261 - 272